Autism & I/DD

Intellectual and developmental disabilities (I/DD) are a physical and/or cognitive impairments that occur before the age of 22. Autism spectrum disorder is generally considered a type of developmental disability that affects behaviour and communication. The autism and I/DD market provides supports and health care services to these populations. Over the past decade, there has been an increase in the changes and challenges affecting I/DD and autism markets—the move to managed care and value-based care, the shift away from residential treatment, the increasing emphasis on consumer-directed care, and new workforce challenges.

Latest Resources

• RWJBarnabas Health & Woods System Of Care Open A New Integrated Health Clinic For People With I/DD In Hamilton, New Jersey
• Illinois Medicaid Moving Institutionalized Consumers To Community Through A Tailored Care Management Initiative
• U.S. v. State of Texas, et al.: HHSC & U.S. Department Of Justice Joint Motion To Dismiss
• Indiana Working Group Recommends Capping Medicaid ABA Services & Setting Sustainable Rates
• SafeinHome Targets $25 Million Funding Round To Expand Remote Supports For Individuals With Intellectual/Developmental Disabilities
• Autism Learning Partners To Open New Centers In California In 2026
• InBloom Opens New Learning Center In Southeast Wisconsin
• Tech Transformation
• More Than Half The U.S. Population Are Living With A Nervous System Disorder
• People With Autism More Likely To Report Suicide-Related Behaviors & Psychological Distress
• Tech-First Independence In Action
• Leadership For Engagement
• FronteraCare Launches Diagnostics Network To Cut Wait Times For Neurodevelopmental Assessments
• Redwood Family Care Network Acquires Minnesota-Based Eagles Wing
• More Children With Autism Report Gastrointestinal Symptoms Vs. Typically Developing Children

See All

HHS Announces Actions To Address Rising Autism Prevalence

At a September 22 press event, President Donald J. Trump and U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. announced actions to address what an accompanying press release described as an “autism spectrum disorder (ASD) epidemic.” Actions include a U.S. Food and Drug Administration (FDA) label update for leucovorin for cerebral folate deficiency, authorizing treatment for children with ASD and enabling state Medicaid programs to cover leucovorin for the indication… Read

• An Executive Perspective: How AI Is Shaping The Future Of Integrated Care
• The State I/DD Challenge
• Medicaid Home & Community-Based Services Waivers Covering The I/DD Population: An OPEN MINDS Market Intelligence Report
• Transition To Work – Second SB 639 Report
• Becoming A Technology-First Organization: The Keystone Human Services Case Study

To sign-up for monthly Autism & I/DD Services alerts, you must be signed in to your account.